A2AR NAM
Solid Tumors (Immuno-oncology)
PreclinicalActive
Key Facts
About Adoram Therapeutics
Adoram Therapeutics is a preclinical-stage biotech company developing allosteric small molecule drugs targeting G-protein-coupled receptors (GPCRs), with a primary focus on immuno-oncology and inflammation. Its lead asset is an A2AR NAM for solid tumors, demonstrating promising preclinical data and nearing clinical candidate stage. The company possesses a proprietary allosteric screening technology and a licensed portfolio, aiming to build a multi-asset pipeline through internal R&D and strategic partnerships.
View full company profileTherapeutic Areas
Other Solid Tumors (Immuno-oncology) Drugs
| Drug | Company | Phase |
|---|---|---|
| SRK-181 | Scholar Rock | Phase 1 |